Grant of Interim Extension of the Term of U.S. Patent No. 4,971,802; MIFAMURTIDE, 58003 [E9-26998]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 216 / Tuesday, November 10, 2009 / Notices
Site 3, Port of Albany, expanding the
site from 35 acres to 277 acres. The
applicant has requested that Site 4,
Crossroads Industrial Park be removed
from FTZ 121. The applicant is also
requesting approval of the following
additional ‘‘magnet sites’’: Site 5, 281
acres, Saratoga Technology + Energy
Park, 10 Hermes Road, Malta, NY 12020;
Site 6, 1192 acres, Luther Forest
Technology Campus, 40 Rocket Test
Station Road, Malta, NY 12020; Site 7,
133 acres, Florida Business Park
Extension, State Highway 5S,
Amsterdam, NY 12010. The applicant
proposes that Site 6 be subject to a
seven-year ‘‘sunset’’ time limit, instead
of the standard five-year ‘‘sunset’’ time
limit that would otherwise apply to
magnet sites under the ASF.
In accordance with the Board’s
regulations, Maureen Hinman of the
FTZ staff is designated examiner to
evaluate and analyze the facts and
information presented in the application
and case record and to report findings
and recommendations to the Board.
Public comment is invited from
interested parties. Submissions (original
and 3 copies) shall be addressed to the
Board’s Executive Secretary at the
address listed below. The closing period
for their receipt is January 11, 2010.
Rebuttal comments in response to
material submitted during the foregoing
period may be submitted during the
subsequent 15-day period (to January
25, 2010)
A copy of the application will be
available for public inspection at the
Office of the Executive Secretary,
Foreign-Trade Zones Board, Room 2111,
U.S. Department of Commerce, 1401
Constitution Avenue, NW., Washington,
DC 20230–0002, and in the ‘‘Reading
Room’’ section of the Board’s Web site,
which is accessible via https://
www.trade.gov/ftz. For further
information, contact Maureen Hinman
at maureen.hinman@trade.gov or (202)
482–0627.
Dated: November 3, 2009.
Elizabeth Whiteman,
Acting Executive Secretary.
[FR Doc. E9–27094 Filed 11–9–09; 8:45 am]
srobinson on DSKHWCL6B1PROD with NOTICES
BILLING CODE 3510–DS–P
VerDate Nov<24>2008
16:45 Nov 09, 2009
Jkt 220001
DEPARTMENT OF COMMERCE
United States Patent and Trademark
Office
[Docket No. PTO–P–2009–0048]
Grant of Interim Extension of the Term
of U.S. Patent No. 4,971,802;
MIFAMURTIDE
AGENCY: United States Patent and
Trademark Office.
ACTION: Notice of interim patent term
extension.
SUMMARY: The United States Patent and
Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for
a third one-year interim extension of the
term of U.S. Patent No. 4,971,802.
FOR FURTHER INFORMATION CONTACT: Raul
Tamayo by telephone at (571) 272–7728;
by mail marked to his attention and
addressed to the Commissioner for
Patents, Mail Stop Hatch-Waxman PTE,
P.O. Box 1450, Alexandria, VA 22313–
1450; by fax marked to his attention at
(571) 273–7728, or by e-mail to
Raul.Tamayo@uspto.gov.
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to a year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On September 30, 2009, IDM Pharma,
agent/licensee of patent owner Novartis,
timely filed an application under 35
U.S.C. 156(d)(5) for a third interim
extension of the term of U.S. Patent No.
4,971,802. Claims of the patent cover
muramyl tripeptide phosphatidyl
ethanolamine, which is labeled as the
active ingredient in the human drug
product Mifamurtide. The application
indicates, and the Food and Drug
Administration has confirmed, that a
New Drug Application for the human
drug product Mifamurtide has been
filed and is currently undergoing
regulatory review before the Food and
Drug Administration for permission to
market or use the product commercially.
Review of the application indicates
that, except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for an additional year as
required by 35 U.S.C. 156(d)(5)(B).
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00015
Fmt 4703
Sfmt 4703
58003
Because it is apparent that the
regulatory review period will continue
beyond the extended expiration date of
the patent (November 20, 2009), interim
extension of the patent term under 35
U.S.C. 156(d)(5) is appropriate.
A third interim extension under 35
U.S.C. 156(d)(5) of the term of U.S.
Patent No. 4,971,802 is granted for a
period of one year from the extended
expiration date of the patent, i.e., until
November 20, 2010.
Dated: October 30, 2009.
David J. Kappos,
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
[FR Doc. E9–26998 Filed 11–9–09; 8:45 am]
BILLING CODE 3510–16–P
DEPARTMENT OF COMMERCE
Bureau of Industry and Security
[Docket No. 0910271381–91382–01]
Impact of Implementation of the
Chemical Weapons Convention on
Commercial Activities Involving
‘‘Schedule 1’’ Chemicals Through
Calendar Year 2009
AGENCY: Bureau of Industry and
Security, Commerce.
ACTION: Notice of inquiry.
SUMMARY: The Bureau of Industry and
Security (BIS) is seeking public
comments on the impact that
implementation of the Chemical
Weapons Convention, through the
Chemical Weapons Convention
Implementation Act and the Chemical
Weapons Convention Regulations, has
had on commercial activities involving
‘‘Schedule 1’’ chemicals during calendar
year 2009. The purpose of this notice of
inquiry is to collect information to assist
BIS in its preparation of the annual
certification to the Congress, which is
required under Condition 9 of Senate
Resolution 75, April 24, 1997, in which
the Senate gave its advice and consent
to the ratification of the Chemical
Weapons Convention.
DATES: Comments must be received by
December 10, 2009.
ADDRESSES: You may submit comments
by any of the following methods:
• E-mail: wfisher@bis.doc.gov.
Include the phrase ‘‘Schedule 1 Notice
of Inquiry’’ in the subject line;
• Fax: (202) 482–3355 (Attn: Willard
Fisher);
• Mail or Hand Delivery/Courier:
Willard Fisher, U.S. Department of
Commerce, Bureau of Industry and
Security, Regulatory Policy Division,
E:\FR\FM\10NON1.SGM
10NON1
]]>Agencies
[Federal Register Volume 74, Number 216 (Tuesday, November 10, 2009)]
[Notices]
[Page 58003]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-26998]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
[Docket No. PTO-P-2009-0048]
Grant of Interim Extension of the Term of U.S. Patent No.
4,971,802; MIFAMURTIDE
AGENCY: United States Patent and Trademark Office.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for a third one-year interim
extension of the term of U.S. Patent No. 4,971,802.
FOR FURTHER INFORMATION CONTACT: Raul Tamayo by telephone at (571) 272-
7728; by mail marked to his attention and addressed to the Commissioner
for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA
22313-1450; by fax marked to his attention at (571) 273-7728, or by e-
mail to Raul.Tamayo@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to a year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On September 30, 2009, IDM Pharma, agent/licensee of patent owner
Novartis, timely filed an application under 35 U.S.C. 156(d)(5) for a
third interim extension of the term of U.S. Patent No. 4,971,802.
Claims of the patent cover muramyl tripeptide phosphatidyl
ethanolamine, which is labeled as the active ingredient in the human
drug product Mifamurtide. The application indicates, and the Food and
Drug Administration has confirmed, that a New Drug Application for the
human drug product Mifamurtide has been filed and is currently
undergoing regulatory review before the Food and Drug Administration
for permission to market or use the product commercially.
Review of the application indicates that, except for permission to
market or use the product commercially, the subject patent would be
eligible for an extension of the patent term under 35 U.S.C. 156, and
that the patent should be extended for an additional year as required
by 35 U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory
review period will continue beyond the extended expiration date of the
patent (November 20, 2009), interim extension of the patent term under
35 U.S.C. 156(d)(5) is appropriate.
A third interim extension under 35 U.S.C. 156(d)(5) of the term of
U.S. Patent No. 4,971,802 is granted for a period of one year from the
extended expiration date of the patent, i.e., until November 20, 2010.
Dated: October 30, 2009.
David J. Kappos,
Under Secretary of Commerce for Intellectual Property and Director of
the United States Patent and Trademark Office.
[FR Doc. E9-26998 Filed 11-9-09; 8:45 am]
BILLING CODE 3510-16-P
